c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
- 31 December 1995
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (13-14), 2185-2190
- https://doi.org/10.1016/0959-8049(95)00344-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Simultaneous analysis of c‐erb B‐2 expression and DNA content in breast cancer using flow cytometryCytometry, 1994
- ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancerCancer Letters, 1994
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- Post-mastectomy megavoltage radiotherapy: The Oslo and Stockholm trialsEuropean Journal Of Cancer, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancerInternational Journal of Cancer, 1991
- Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situBreast Cancer Research and Treatment, 1991
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- A point mutation in the neu oncogene mimics ligand induction of receptor aggregationNature, 1989
- Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trialsInternational Journal of Radiation Oncology*Biology*Physics, 1989